Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Atrasentan is an antagonist of endothelin receptor type A (ETA; Ki = 69 pM for the human receptor).1 It is selective for ETA over ETB (Ki = 139 nM for the human receptor) and a panel of 29 other receptors at 10 µM. Atrasentan inhibits endothelin-1-induced secretion of arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) from human pericardial smooth muscle cells (HPSMCs; pA2 = 10.5), as well as endothelin-1-induced vasoconstriction in isolated rat aortic rings (pA2 = 9.2). It inhibits endothelin-1-induced increases in the pressor response in normotensive rats when administered at a dose of 10 mg/kg. Atrasentan (5 mg/kg per day) reduces urinary levels of albumin, TGF-β, and a prostaglandin E2 metabolite, as well as decreases the number of macrophages in the renal cortex, in a rat model of streptozotocin-induced diabetic nephropathy.2
WARNING This product is not for human or veterinary use.
1. Pharmacological characterization of A-
2. Endothelin A receptor blockade reduces diabetic renal injury via an anti-